O htahara syndrome (OS), or early infantile epileptic encephalopathy, and early myoclonic encephalopathy (EME) comprise a group of early onset epileptic encephalopathies with burst suppression (EOEE-BS). Onset is within the first 3 months of life, most often within 1 month. In OS, spasms are the predominant seizure type. In EME, myoclonic seizures predominate, nonepileptic myoclonus is common, and burst suppression may be more prominent in sleep. Although historically depicted as separate entities, OS and EME have more recently been considered part of a spectrum, with overlap in clinical presentation and etiology; we will use the broader term EOEE-BS to encompass both syndromes. [1] [2] [3] [4] Known genetic causes of EOEE-BS include brain malformations (eg, polymicrogyria and lissencephaly), inborn errors of metabolism (eg, pyridoxine-and other vitamin-dependent epilepsies, mitochondrial disorders, and amino acidopathies), and other genetic etiologies (eg, pathogenic variants in ARX, KCNQ2, SCN2A, SIK1, SLC25A22, STXBP1). 2,5-13 Based on current literature, single gene variants explain at least 20 to 30% of epileptic encephalopathies. [14] [15] [16] We sought to determine the contribution of genetic etiologies to EOEE-BS and to delineate genotype-phenotype correlations in a cohort of patients with EOEE-BS without malformations of cortical development. We highlight the importance of identifying genetic causes for young patients with refractory epilepsy who could potentially benefit from gene-based treatments in this era of emerging precision medicine. 17 
Patients and Methods

Cohort Ascertainment and Phenotypic Analysis
Patients were recruited locally at Boston Children's Hospital, through collaborating researchers and physicians, and Aaron's Ohtahara Foundation (www.ohtahara.org), a family support organization. This study was approved by the Boston Children's Hospital Institutional Review Board. All patients had been diagnosed with OS or EME by treating pediatric neurologists. We reviewed history obtained from medical records and from families via telephone and/or written surveys, including birth history, seizure types and frequency, physical examination features, developmental history, family history, and clinical genetic/metabolic evaluations. We reviewed primary electroencephalography (EEG) and magnetic resonance imaging (MRI) original data and reports as available. MRIs were reviewed with a neuroradiologist (E.Y.) in 26 patients (1-11 MRIs/patient); original images were not available in the remainder, for whom reports were reviewed. We visually assessed overall volume, ventricle size, sulcal widening, callosal and white matter volume, gray matter volume, cortical morphology, cerebellar volume or malformation, myelination, focal signal abnormality, prior injury, diffusion abnormality, mass effect, basal ganglia, spectroscopy, visual pathways, and the pituitary gland. EEGs before 3 months of age or first available EEG was reviewed by pediatric epileptologists (A.M.B., A.P., H.E.O.) in 17 patients. Original tracings were not available in the remainder, for whom reports were reviewed. We evaluated background features and epileptiform activity of neonatal EEGs according to American Clinical Neurophysiology Society guidelines. 18 Burst suppression was defined as an invariant pattern with periods of suppression <5 mV alternating with periods of high-amplitude bursts of activity, devoid of normal waking and sleep features, and lacking reactivity. 18, 19 Based on available data and the above criteria, we classified cases as EOEE-BS versus other severe EOEE without a specific electroclinical syndrome. We include in this report patients without malformations of cortical development. Our analysis focuses on 28 patients with confirmed EOEE-BS. We report in parallel the genetic analysis of 5 patients with similar clinical presentation without confirmed burst suppression.
Genetic Analysis
We reviewed all clinical genetic testing performed for each case. When a clinical genetic diagnosis was not available, we performed research-based genetic assessment. One patient was diagnosed by a research gene panel, and the remainder (n 5 23) underwent exome sequencing to investigate known or novel genetic causes. DNA extracted from blood or saliva underwent whole exome sequencing capture using either the Agilent Technologies (Santa Clara, CA) SureSelect XTHuman All Exon v4 or Illumina (San Diego, CA) Rapid Capture Exome enrichment kit. Sequencing of 100bp paired-end reads was obtained using Illumina HiSeq. Coverage was >90% or >80% meeting 20 3 coverage with the two methods, respectively. The pipeline for data analysis in both cases included alignment and quality score recalibration with Burrows-Wheeler Aligner (biobwa.sourceforge.net/) and variant calling with GATK (www.broadinstitute.org/gatk/). Variant annotation, filtering, and interpretation were completed with the assistance of XBrowse (https://atgu.mgh.harvard.edu/xbrowse). Clinical chromosomal microarray results were available in 23 of 33 patients.
We described variants using human genome 19 (hg19) coordinates. We used inheritance pattern, in silico predictions, control databases (including the Exome Aggregation Consortium [ExAC], Exome Variant Server, 1000 Genomes database, and dbSNP), clinical laboratory reports, and findings in the literature to assess pathogenicity. For candidate genes, we prioritized de novo heterozygous, compound heterozygous, or homozygous variants in genes with a plausible role in epilepsy. After assessing known epilepsy genes, we considered other candidate genes. Variants considered pathogenic or likely pathogenic were confirmed by polymerase chain reaction.
Statistical Analysis
Descriptive statistics were applied as indicated. Fisher exact test was used to compare proportions of patients with resolution of burst suppression before 2 months. The Mann-Whitney U test was used to compare timing of seizure onset in the group with likely pathogenic KCNQ2 variants versus the remainder of the cohort, with a 2-tailed p-value of < 0.05 considered significant in both cases.
Results
Cohort
We studied 33 patients with a referral diagnosis of OS or EME without malformations of cortical development. After reviewing EEG data and/or reports, we confirmed early burst suppression in 28 patients, whom we classified as EOEE-BS. The remaining 5 patients (Patients 12, 13, 17, 30, and 33) had abnormal early EEGs but did not have confirmed burst suppression. Of these 5 patients, 2 had excess discontinuity with multifocal sharp waves, 2 had multifocal sharp waves without discontinuity, and 1 had a normal background initially but evolved to transient burst suppression at 5 months, then hypsarrhythmia. They were classified as other severe EOEE without a specific electroclinical syndrome. We performed genetic analysis of these cases based on the referral diagnosis of EOEE given by their treating pediatric neurologists. Of the 28 patients with EOEE-BS, 5 were born preterm (range 5 30-36.5 weeks) and the remainder at term. Median age of seizure onset was 1 day (range 5 1 day-3 months). Seizure types at onset included spasms and myoclonic, tonic, or focal motor seizures ( Table 1 ). All had active seizures at last follow-up except one; all had persistently abnormal EEGs. Patients were followed for a median of 15.6 months (range 5 1 month-18 years) to last follow-up or death. In 23 of 28 (82%) patients with EOEE-BS, burst suppression resolved with evolution to another epileptic encephalopathy pattern by median age 3.5 months (range 5 1-16 weeks; see Table 1 ). In 4 of 28 (14%) patients with EOEE-BS, burst suppression persisted at last EEG (range 5 1.3-6 months). One patient had no follow-up EEGs. Three of 28 progressed to West syndrome.
All patients with EOEE-BS had severe global developmental delay or intellectual disability at last follow-up. Physical examinations reported normal occipitofrontal circumference in 23, microcephaly in 4 (3 congenital, 1 acquired), and head size unknown in 1 patient; central pattern of hypotonia or spastic quadriparesis in all; visual impairment (likely cortical) in all when adequate information was available; and abnormal movements in 8 (myoclonus, chorea, or tremors). Eleven (39%) died between 33 days and 7.6 years. Clinical details are summarized in Table 1 (Patient 19) . Thirteen patients had diffusely low cerebral volume either on initial MRI or development of volume loss over time. Nine had delayed or abnormal myelination. Four had findings of uncertain significance in relationship to the epileptic encephalopathy (transverse sinus thrombosis, intraventricular hemorrhage, arachnoid cyst, germinolytic and connatal cysts). No findings were specifically associated with a given gene. Notably, 2 patients (Patients 8 and 31) had evidence of hypoxic-ischemic injury on neuroimaging, but this did not exclude genetic etiology. In 1 of these 2 individuals (Patient 8), we observed a pathogenic variant in KCNQ2. There was also a patient in the group without burst suppression who had neuroimaging findings suggestive of central hypoxic-ischemic injury as well as a likely pathogenic variant in SCN2A (Patient 17). The clinical course of these 3 patients deviated from that expected for the degree of hypoxic-ischemic injury.
Metabolic Testing
Whereas several patients had metabolic abnormalities of unclear relationship to their EOEE-BS, only 1 patient (Patient 18) had a metabolic derangement clearly linked to the underlying diagnosis. This patient had a low cerebrospinal fluid (CSF) pyridoxal-5-phosphate (P5P) level in the setting of a subsequently identified homozygous PNPO pathogenic variant. One patient had high phenylalanine in association with a diagnosis of phenylketonuria (Patient 26), which was treated early and did not explain her OS phenotype.
Among the 5 patients without burst suppression, Patient 13, with a deletion including STXBP1, had low CSF folate (not while taking valproic acid). She initially responded to folinic acid, as has 1 case in the literature, 20 with improvement in seizures and development. The effect waned over years.
Identification of Variants in Known DiseaseAssociated Genes
Based on clinical and research genetic testing including exome sequencing when clinical testing was negative, we identified the following known or suspected genetic causes of EOEE-BS in 28 patients: 10 patients (35.7%) each with a likely or known pathogenic variant in KCNQ2 that was disease-associated and/or that we established as de novo; 2 patients (7.1%) each with an established or presumed de novo STXBP1 pathogenic variant, including 1 partial gene deletion; 2 patients (7.1%) each with a de novo SCN2A likely pathogenic variant; 1 patient (3.6%) with a homozygous PNPO pathogenic variant; 1 patient (3.6%) with a hemizygous PIGA likely pathogenic variant; and 1 patient (3.6%) with a homozygous likely pathogenic SEPSECS variant (Tables 1 and   2 ). In the 5 patients without confirmed burst suppression, we identified the following known or suspected genetic causes of epileptic encephalopathy: 2 patients (Patients 12 and 13) with pathogenic variants in STXBP1 and 1 patient with a suspected pathogenic variant in SCN2A. The overall yield of 61% with known or suspected genetic causes in the group with confirmed burst suppression is comparable to the yield of 60% in the group without confirmed suppression, and the genetic 
KCNQ2 Subgroup
Likely pathogenic and pathogenic variants in KCNQ2 identified in our series were all heterozygous missense variants in exons 4 to 7 and 15 (see Table 2 ). The domains affected included the transmembrane domains, cytoplasmic domains, and the pore-forming domain. Six of the 10 identified variants were previously reported, including 2 with different missense variants affecting the same amino acid position also reported; 1 of these was identified in 2 unrelated patients in our series (Patients 5 and 6). 9, 24, [27] [28] [29] Tonic seizures and/or spasms were present at last follow-up in all patients except 1 who was seizure-free at last follow-up. There was a trend toward earlier seizure onset in the KCNQ2 cohort compared to the rest of the cohort, which did not meet statistical significance (Mann-Whitney U test, p 5 0.08), specifically within the first week for all 10 patients in the KCNQ2 cohort compared to 10 of 18 patients in the rest of the EOEE-BS cohort. All 10 had burst suppression identified by 1.5 months, resolving by 2 months in 8 of 10 (range 5 1 week-5 months, median 5 1.25 months). This is a higher proportion of patients with resolution of burst suppression by 2 months compared to the other patients in the cohort (Fisher exact test, p < 0.001). Earlier resolution of burst suppression did not appear to correlate with better clinical outcome with regard to epilepsy, development, or survival (3 of 10 died). There was no clear pattern of medication response. Only 2 patients tried ezogabine, a potassium channel opener. One patient had an early positive response but developed a rash that necessitated treatment cessation. In the second patient, treatment had to be stopped due to urinary retention. Neuroimaging showed low volume in 6 of 10 (acquired/ progressive in 2, mild and stable or only 1 time point available in 4), delayed or dysmyelination in 5 of 10, and evidence of central hypoxic-ischemic injury in 1. Motor examination demonstrated spasticity in all but 2 patients (2 months and 1.3 years at last follow-up, respectively). Two patients had nonepileptic myoclonus (Patients 1 and 3) .
The KCNQ2 subgroup was similar in clinical presentation to the series of 8 patients with KCNQ2 variants reported by Weckhuysen and colleagues and to other reports of KCNQ2-related epileptic encephalopathy. 9, 24, [27] [28] [29] One difference is that 9 of 10 patients in our series had seizures at last follow-up (range 5 1 month-4 years, mean 5 1.9 years), whereas 7 of 8 patients in their series had offset of seizures at age range 9 months to 4 years. 9 With regard to neuroimaging, deep gray matter signal abnormalities have been reported to occur transiently. 9 Although technical differences across MRIs from different sites are a potential confounder, our KCNQ2 cohort did not demonstrate patterns of basal ganglia signal abnormality that were clearly distinct from normal signal, and the thalamic signal increase was not found in our cohort. The decreased white matter volume and abnormal myelination reported in a subset of patients is similar to those seen commonly in our cohort but not specific to KCNQ2.
9
STXBP1 Subgroup
Pathogenic variants in STXBP1, similar to reported variants, were found in 2 patients with confirmed burst suppression (1 deletion, 1 missense) and 2 patients without confirmed burst suppression (1 splice site, 1 frameshift; see Table 2 ). 7, 8, [30] [31] [32] [33] [34] [35] Two of the 4 patients had burst suppression identified at approximately 2 months, resolving by 4 months and 13 months, respectively. Two patients did not have burst suppression after careful review of EEGs. All 4 patients had prominent spasms in the first 3 months of life. They had tonic seizures, spasms, or head drops at last follow-up, ranging from 13 months to 16 years. Neuroimaging was normal except for mild hypoplasia of the corpus callosum in 1 patient. Motor examination showed spasticity in 3 and diffuse hypotonia in 1 (Patient 12). Despite literature reports of movement disorders, the only abnormal movements noted were hand stereotypies in 1 patient without burst suppression (Patient 13).
36
SCN2A Subgroup
Likely pathogenic missense variants were identified in the gene SCN2A in 3 patients: 2 with confirmed burst suppression identified in the first week of life, evolving within 2 months including a period of modified hypsarrhythmia, and 1 with high-amplitude multifocal sharp waves at 2 weeks but no identified burst suppression. None was previously reported in the literature; all were de novo and absent from control databases. One patient (Patient 15) had a different missense variant at the same amino acid position as a variant identified in a family with benign familial neonatal-infantile seizures. 37 Tonic seizures and spasms were prominent early in all 3 patients. Neuroimaging was normal in 1 patient, showed diffuse atrophy in another, and was suggestive of central hypoxic-ischemic injury in the third. Motor examination demonstrated spasticity in the 2 patients with follow-up beyond the first year and diffuse hypotonia in 1 patient with follow-up up to 6 weeks of life. None had abnormal movements.
Other Genes, Known or Novel Association with Burst Suppression
The patient with a PNPO homozygous variant (Patient 18) was born prematurely at 33 weeks gestation, presented with spasms and focal clonic seizures on day of life 1, and had burst suppression on the first documented EEG at 2.5 months. The EEG evolved to an abnormal but continuous background with multifocal sharp waves by 3.5 months. Neuroimaging showed diffuse lowvolume and nonocclusive transverse sinus thrombosis. The patient had normal head growth, pigmentary retinopathy, diffuse hypotonia, and hyperkinetic movements. The patient with the hemizygous PIGA variant (Patient 20) was born prematurely at 30 weeks gestation and had onset of focal motor and likely myoclonic seizures at <10 days. He had burst suppression on first available EEG documentation at 4.5 months, which evolved at 5 months to hypsarrhythmia. Neuroimaging showed dysgenesis of the corpus callosum. The patient had a cleft palate, diffuse hypotonia evolving to spasticity, chorea, and tremors. Although facial dysmorphisms were described in the 4 previously reported patients with PIGA pathogenic variant-associated epileptic encephalopathy, cleft palate and movement disorder were not described. 38 The patient with the homozygous SEPSECS variant (Patient 19) was born at term and had onset of spasms at 3 weeks. He had burst suppression on first available EEG at 5 months, evolving at 12 months to hypsarrhythmia then later to generalized slowing with multifocal sharp waves. Neuroimaging was notable for cerebral more than cerebellar volume loss, consistent with the known association of SEPSECS variants with autosomal recessive progressive cerebellocerebral atrophy. 21 This patient also presented with microcephaly and diffuse hypotonia.
Patients without Identified Genetic Etiology
For 11 patients with EOEE-BS and 2 without early burst suppression, a genetic etiology was not definitively identified. In 7 of 13 patients, genetic variants of uncertain significance were identified (Supplementary Table 3) . At this point, there is insufficient evidence to classify the variants as being likely or known pathogenic in the context of the patients' histories. INPP4A is a strong candidate gene for Patient 26. There is a single previously reported patient with a homozygous INPP4A variant with microcephaly, severe developmental delay, cortical visual impairment, infantile onset myoclonic epilepsy, and cerebellar hypoplasia who had a similarly affected deceased brother. 39 Patient 26 did not have cerebellar hypoplasia but shared the other features. Eleven of 13 patients had chromosomal microarray testing, and 2 patients had duplications in known genomic hotspots for copy number variation in association with epilepsy, 1 in 16p11.2 (Patient 22) and 1 in 15q11.2 between breakpoints 1 and 2 (Patient 28); however, these were not felt to fully explain the severe epileptic encephalopathy phenotype. 40, 41 Of these 13 patients, 11 had burst suppression identified between the first week of life and 3 months. One (Patient 30) had an initial normal EEG evolving after 3 months through transient periods of burst suppression and hypsarrhythmia. Another patient (Patient 33) had initial excess discontinuity then generalized slowing with nearly continuous biposterior sharp waves. EEG evolution in the 11 patients with EOEE-BS included persistent burst suppression in 4 patients, a period of hypsarrhythmia or modified hypsarrhythmia in 6 patients, and no follow-up in 1 patient. Myoclonic seizures were predominant at onset in 6 patients (3 with spasms as well), whereas myoclonic seizures were prominent at onset in only 2 patients with identified genetic (KCNQ2) variants. Neuroimaging in the 11 patients with EOEE-BS was normal for age initially in 8 patients, showed nonspecific diffuse atrophy in 3, demonstrated evidence of hypoxic-ischemic injury in 1, and demonstrated abnormal T2 signal in the deep gray matter of 3 (2 of these cases may be explained by vigabatrin exposure). The patients without burst suppression both had volume loss, and 1 (Patient 33) had thick perisylvian cortex without polymicrogyria (see Supplementary Tables 1  and 2 ). To summarize all 13 patients with and without burst suppression together, 2 had congenital microcephaly and 11 had normal head growth. Motor examination demonstrated either diffuse hypotonia or spastic quadriparesis. 
Discussion
This study provides insight into the genetic landscape of EOEE-BS, including OS and EME, as well as detailed phenotypic evaluation by genetic subtype. Pathogenic variants in known genes explain >60% of cases of EOEE-BS, encompassing the syndromes OS and EME, in patients without a cortical malformation. We newly associate the gene SEPSECS with EOEE-BS in a single case and identify a strong candidate gene INPP4A. Additional cases would confirm these associations. The early seizure types varied such that strict classification into OS or EME is challenging and does not differentiate genetic etiology. Prominent myoclonic seizures at onset (as in EME) were overrepresented in patients without an identified genetic etiology.
At 61%, the frequency of pathogenic variants in this study is higher than previous reports of a 20 to 30% yield from exome sequencing in early life epileptic encephalopathy. [14] [15] [16] These prior studies did not focus on EOEE-BS; each evaluated a broader group of epileptic encephalopathies including those with older age of onset than our cohort. [14] [15] [16] In patients with early life epilepsy (onset at < 3 years) enrolled through the Pediatric Epilepsy Research Consortium, the yield of diagnosis with clinical genetic testing (predominantly including epilepsy gene panels and chromosomal microarray testing) was 27 to 33%. 42 There have been several reports of yield for specific genes including KCNQ2, STXBP1, and SCN2A within EOEE-BS and severe overlapping epileptic encephalopathy. 5, [7] [8] [9] This is, however, the first comprehensive report of genetic etiologies in a cohort of patients with clinical diagnosis of OS or EME without brain malformations. Our subjects were referred either locally at Boston Children's Hospital, through the family support group Aaron's Ohtahara Foundation, or through collaborating physicians. Although our cohort may have a referral bias, it was likely biased toward enrollment of patients without a clinical explanation; thus, we do not think that we have overestimated the role of genetic influence on EOEE.
The largest genetic subgroup we identified was the group of patients with KCNQ2 variants, comprising 35.7% of this series of 28 patients with EOEE-BS and 30% of the total 33 patients enrolled with severe EOEE without malformations. This is higher than the 10% yield of KCNQ2 pathogenic variants in a similar previously reported series of patients with unexplained neonatal or early infantile seizures and psychomotor retardation. 9 Frequency of variants in STXBP1 and SCN2A in this cohort is within expected parameters based on prior reports. 5, 7, 8 Overall, it is clear that variants in these 3 genes, KCNQ2, STXBP1, and SCN2A, are among the most frequent causes of EOEE-BS. However, it is evident that EOEE-BS is highly heterogeneous in terms of genetic etiology. For the KCNQ2 subgroup, clinical presentation is similar to the prior report, except for the absence of deep gray signal abnormalities on neuroimaging. 9 We speculate some of these differences could reflect differences in age at time of MRI and in MRI acquisition. Our data suggest that prominent early and persistent tonic seizures and spasms, and early resolution of burst suppression, may be features suggestive of a KCNQ2 pathogenic variant. Most of the metabolic abnormalities were nonspecific with 1 exception (low CSF P5P in a patient with a pathogenic PNPO homozygous variant), emphasizing the need for evaluating metabolic causes and seeking a specific molecular diagnosis. Otherwise, we did not observe clear phenotypic distinctions between the genetic subgroups, especially early in the clinical course. Phenotyping relied on clinical reports rather than primary data in some cases, but this is not expected to skew results in a particular direction.
Imaging evidence of hypoxia-ischemia did not exclude a genetic diagnosis in our series. This finding suggests that genetic evaluation should be considered for patients in whom hypoxic-ischemic encephalopathy (HIE) is expected to be the cause of early seizures if the clinical course varies from that expected for the degree and pattern of HIE.
We provide further support for the role of the gene PIGA and new evidence for the role of the gene SEP-SECS in the pathogenesis of EOEE-BS. Four PIGA variants in 6 patients with EOEE have been reported, including 1 variant (p.R412X) associated with neonatal onset with burst suppression in 3 patients. 38 ,43 Thus, our patient's variant is only the second unique variant in PIGA identified in association with EOEE-BS, and represents a different mechanism from the other genetic causes of EOEE-BS. This finding supports further investigation for pathogenic variants in genes with overlapping roles in glycosylphosphatidylinositol biosynthesis as potential additional causes of EOEE-BS in other patients. Pathogenic variants in SEPSECS are an identified cause of progressive cerebellocerebral atrophy and are associated with early life epilepsy, but this is the first report of association with EOEE-BS. [21] [22] [23] Previously reported patients had epilepsy onset ranging from 11 months through the second year of life, with seizure types including infantile spasms and myoclonic seizures. [21] [22] [23] Disruption of selenoprotein biosynthesis, as caused by pathogenic variants in this gene, is another likely molecular cause of EOEE-BS. 21 In this era of evolving rational therapy and precision medicine in epilepsy, having an established genetic diagnosis often influences treatment. EOEE-BS is typically refractory to medications, and thus even modest improvements in quality of life from directed therapy would be valuable. In the case of vitamin-dependent epilepsies, treatment with pyridoxine, folinic acid, or P5P is critical. 44 For more recently established treatments, efficacy remains to be determined and in some cases requires knowledge of which variants are loss or gain of function.
For example, ezogabine is an antiepileptic drug acting on potassium channels and may be beneficial in patients with loss of function KCNQ2 pathogenic variants, although formal studies have yet to be performed. 45, 46 Although many variants are considered dominant negative, some may in contrast enhance potassium channel activity. 47, 48 Care must be taken to adequately assess the type and degree of dysfunction, which can be done through emerging international collaborative efforts centered around KCNQ2 such as the Rational Intervention for KCNQ2/3 Epileptic Encephalopathy Project (www. RIKEE.org). Sodium channel-acting medications, such as phenytoin in particular, appear to be most beneficial in patients with gain of function SCN2A pathogenic variants. 49 We conclude that the majority of children with EOEE without structural malformations have identifiable genetic etiologies. Genetic testing should now be pursued on a clinical basis to arrive at a definitive diagnosis, put an end to needless additional laboratory investigations, and potentially drive treatment decisions. In addition, a genetic diagnosis can empower families with the knowledge that they need to care and advocate for their children as well as to make decisions regarding family planning. Appropriate and timely clinical diagnosis is already impacting treatment. Finally, in this era of precision medicine, it is important that infants with epilepsy be appropriately diagnosed to be eligible for gene-specific clinical trials as they emerge. In conclusion, our findings together suggest that early and efficient genetic testing would be of high yield and clinical benefit for patients with EOEE-BS and other cases of severe EOEE resembling OS and EME. this project; and F. Zhao and Dr D. MacArthur at the Broad Institute (Cambridge, MA) and Dr S. Hill at Boston Children's Hospital for technical assistance with data processing.
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